Pharmacy and Medical Billing Guidance for SPRAVATO® (esketamine)

Effective May 12, 2022, New York State (NYS) Medicaid fee-for-service (FFS) and Medicaid managed care (MMC) plans [including Mainstream MMC Plans, Human Immunodeficiency Virus (HIV) Special Needs Plans (HIV-SNPs), and Health and Recovery Plans (HARPs)] will implement the following billing guidance for SPRAVATO® (esketamine) in the Medicaid program.

You need to be logged in to view the rest of the content. Please . Not a Member? Join Us

Discover more from Doctor Trusted

Subscribe to get the latest posts sent to your email.

Discover more from Doctor Trusted

Subscribe now to keep reading and get access to the full archive.

Continue reading